VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | Management of CRS and ICANS after CAR-T therapy for ALL

Vipul Sheth, PhD, Fred Hutchinson Cancer Research Center, Seattle, USA, comments on the management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric-antigen receptor T-cell (CAR-T) therapy for patients with acute lymphoblastic leukemia (ALL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter